Table 6 Univariate and multivariate analysis with overall survival for cT1 breast cancer
From: Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer
Parameters | Univarite analysis | Multivarite analysis | ||||
|---|---|---|---|---|---|---|
Hazard ratio | 95% CI | p value | Hazard ratio | 95% CI | p value | |
Age at operation (years old) | ||||||
  ≤ 60 vs > 60 | 2.351 | 0.809–7.677 | 0.117 |  |  |  |
Tumor size (mm) | ||||||
  ≤ 10.0 vs > 10.0 | 1.323 | 0.412–5.861 | 0.660 |  |  |  |
Estrogen receptor | ||||||
 Negative vs Positive | 3.092 | 0.612–56.249 | 0.202 |  |  |  |
Progesterone receptor | ||||||
 Negative vs Positive | 2.809 | 0.876–12.425 | 0.085 | 2.654 | 0.824–11.770 | 0.106 |
HER2 | ||||||
 Negative vs Positive | 0.870 | 0.048–4.383 | 0.892 |  |  |  |
Ki67 | ||||||
  ≤ 20% vs > 20% | 2.381 | 0.649–7.178 | 0.174 |  |  |  |
Intrinsic subtype HRBC | ||||||
 No vs Yes | 2.596 | 0.515–47.194 | 0.292 |  |  |  |
Intrinsic subtype HER2BC | ||||||
 No vs Yes | – | – | 0.243 |  |  |  |
Intrinsic subtype TNBC | ||||||
 No vs Yes | 0.571 | 0.031–2.879 | 0.559 |  |  |  |
Pathological axillary lymph node metastasis | ||||||
 No metastasis vs Metastasis | 0.858 | 0.133–3.150 | 0.838 |  |  |  |
Lymph vascular invasion | ||||||
 No vs Yes | 1.324 | 0.406–3.839 | 0.621 |  |  |  |
Hyperlipidemia | ||||||
 No vs Yes | 2.373 | 0.727–6.910 | 0.143 |  |  |  |
Multiple medicine types for hyperlipidemia | ||||||
 No vs Yes | 6.109 | 0.335–31.184 | 0.169 |  |  |  |
Statins | ||||||
 Non-user vs User | 2.605 | 0.798–7.578 | 0.107 | 2.425 | 0.742–7.057 | 0.134 |
Lipophilic statins | ||||||
 Non-user vs User | 2.287 | 0.355–8.449 | 0.328 |  |  |  |
Hydrophilic statins | ||||||
 Non-user vs User | 2.253 | 0.508–7.247 | 0.251 |  |  |  |
Fibrate | ||||||
 Non-user vs User | 7.765 | 0.424–40.367 | 0.131 |  |  |  |
Nicotinic acid (tocopherol acetate) | ||||||
 Non-user vs User | – | – | 0.591 |  |  |  |
Sterol absorption inhibitors (ezetimibe) | ||||||
 Non-user vs User | – | – | 0.672 |  |  |  |